Allogeneic hematopoietic cell transplantation (alloHCT) is a vital therapy for various hematologic diseases, though it demands high physiological resilience. Frailty, a syndrome impacting the body’s ability to withstand stress, affects outcomes of alloHCT across all ages.This study examines the relationship between frailty and peri-transplant activity and sleep patterns using Fitbit® devices. In this pilot study, adults scheduled for their first myeloablative alloHCT at the University of Minnesota from June 2022 to January 2023 were included if they had a compatible device for the Fitbit® app. Participants were monitored for activity and sleep from admission to day +30 post-transplant. Frailty was assessed pre-transplant using Fried Phenotype criteria. Data were analyzed for activity and sleep patterns differences among not frail, pre-frail, and frail groups. Nine patients provided sufficient data for analysis, showing significant variances in activity levels and sleep patterns across frailty categories. Not frail patients exhibited significantly higher daily steps and active minutes than pre-frail and frail patients. Not frail patients also had the highest amount of restorative deep and rapid eye movement sleep. Due to Fitbit methodology and likely frequent interruptions, 28% of the days in the first month post-transplant had a recorded sleep time of 0 minutes. Although our sample size was small, our findings underscore the importance of frailty in influencing activity and sleep patterns among alloHCT recipients.

The authors have declared no competing interest.

This study was funded by the Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study (STUDY00011670) was approved by the University of Minnesota Institutional Board Review.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Reasonable requests for data can be sent to the corresponding author.